Prevalence of NUDT15 (nudix hydrolase 15) and ITPA (inosine triphosphate pyrophosphohydrolase) mutation and their relation to clinical outcome in pediatric cancer patient receiving mercaptopurine at Phramongkutklao hospital

Prevalence of NUDT15 (nudix hydrolase 15) and ITPA (inosine triphosphate pyrophosphohydrolase) mutation and their relation to clinical outcome in pediatric cancer patient receiving mercaptopurine at Phramongkutkla

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20190828003

Enrollment

Registered

2019-08-28

Start date

2018-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To study the effect of NUDT15 and ITPA mutations to patients&#039

Interventions

All pediatric oncology patients who is treated with mercaptopurine

Diagnostic

Pediatric oncology patients

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: - Aged 0-18 years of age - History of cancers and treated at Phramongkutklao Hospital - History of treatment with 6-mercaptopurine

Exclusion criteria

Exclusion criteria: - No medical records or laboratory records identified - History of allergy to 6-mercaptopurine - Contraindication for using 6-mercaptopurine

Design outcomes

Primary

Measure	Time frame
Prevalence of NUDT15 and ITPA mutations All patients followed up in 2 years period Frequency and percentage	—

Secondary

Measure	Time frame
Effect of NUDT15 and ITPA mutations to clinical outcomes All patients followed up in 2 years period Binary Logistic Regression	—

Countries

Thailand

Contacts

Public ContactPiya Rujkijyanont

Phramongkutklao Hospital and College of Medicine

piya_rujk@yahoo.com0910034585

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026